<DOC>
<DOCNO>
EP-0005055
</DOCNO>
<TEXT>
<DATE>
19791031
</DATE>
<IPC-CLASSIFICATIONS>
C07C-205/00 C07D-337/12 A61P-25/00 A61P-25/04 A61K-31/38 C07C-205/57 A61P-29/00 C07D-337/00 
</IPC-CLASSIFICATIONS>
<TITLE>
6,11-dihydrodibenzo-thiepin-11-ones and their s-oxides, methods for their preparation and pharmaceutical compositions containing them
</TITLE>
<APPLICANT>
syntex incus <sep>syntex (u.s.a.) inc.<sep>syntex (u.s.a.) inc. 3401 hillview avenue palo alto california 94303 us<sep>
</APPLICANT>
<INVENTOR>
ackrell jackus<sep>ackrell, jack<sep>ackrell, jack192 websterpalo alto california 94301us<sep>
</INVENTOR>
<ABSTRACT>
novel 6, 11-dihydrodibenzo-[b. e. ]-thiepin-11-one s-oxides, and intermediates useful in the preparation thereof, having the formulae <chem> wherein r is hydrogen, an alkyl group containing from 1 to twelve carbon atoms or a pharmaceutically acceptable salt thereof when r is hydrogen, r<1> is hydrogen, chloro or methoxy, r<2> is hydrogen or methyl, and r<3> is chloro or methoxy.  the free acid or ester of compound ii, or its 8-r<3> unsubstituted equivalent, can be converted to the corresponding compound i by oxidation.  the compounds and compositions containing them can be used for treating inflammation or other conditions in mammals. 
</ABSTRACT>
<DESCRIPTION>
novel 6, 11-dihydrodibenzo-thiepin-11-one s oxides, methods of preparation, compositions and uses thereof and intermediates useful in the preparation thereof this invention relates to pharmaceutically usef 6, 11-dihydrodibenzo-[b.e. ]-thiepin-11-ones. japanese patent publication no. 425/72, published january 7, 1972, broadly discloses compounds of the formula: emi1.1 wherein r1 , r2 and r3 are each a hydrogen atom or a lower alkyl group (e.g. methyl, ethyl, propyl and isopropyl); x is a hydrogen atom, a halogen atom (c1, br, i and f) or a lower alkyl group; and y is an oxyger atom, -ch2s-, or emi1.2 (wherein r4 is a hydrogen atom or a lower alkyl group) or the salt thereof; and specifically names in example 3 thereof ll-oxo-6,11-dihydro-dibenzo [b.e.] thiepin-2yl-acetic acid. german ols 24 42 060, laid open may 7, 1975, broadly discloses oxepin compound of the formula: emi2.1 4 wherein x is c=o, chc1, chbr, ch2, or chor ; y is alkyl of from 1 to 4 carbon atoms, alkoxy of from 1 to 4 carbon atoms, halogen or trifluoromethyl; n is an integer 0, 1, 2 or 3; z is coor5, ch2or5, conr25 or conhor5; and rú to r5 are hydrogen, or alkyl of from 1 to 4 carbon atoms. certain oxepin compounds are also disclosed in belgian patent no. 818,055, laid open november 18, 1974. compounds within the formula emi2.2 where r2 and r4 are defined hereinafter, are described in u.s. patents nos. 4000288 and 4000308. however it has now been found, as further described hereinafter, that the corresponding s-oxides exhibit certain improved properties compared with the non-s-oxides. the compounds of the present invention have the formulae: emi2.3 emi3.1 wherein r is hydrogen, an alkyl group containing from one to twelve carbon atoms or a pharmaceutically acceptable salt thereof when r is hydrogen, r1 is hydrogen, chloro or methoxy7 r2 is hydrogen or methyl1 and r3 is chloro or methoxy. also included in this invention are compositions and methods of use for the compounds formulas (i) and (11). the term "alkyl" refers to and includes branched and straight chain hydrocarbons containing from one to twelve carbon atoms. typical alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, tertiary butyl, isoamyl, neopentyl, isopentyl, hexyl, octyl, nonyl, isodecyl, 6-methyldecyl, dodecyl, and the like. the term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. salts derived from inorganic bases include sodium, potassium, lithium, ammonia, calcium, magnesium, ferrous, zinc, copper, manganous, aluminum, ferric, manganic salts and the like. particularly preferred are the ammonia, potassium, sodium, calcium and magnesium salts. salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, tromethamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, n-ethylpiperidine, polyamine resins and the like. particularly preferred organic non-toxic bases are isopropylamine, diethylamine, ethanolamine, piperidine, tromethamine, choline and
</DESCRIPTION>
<CLAIMS>
claims:      1.    a compound selected from those having the formula: emi51.1       wherein r is hydrogen, an alkyl group containing from one to twelve carbon atoms, or a pharmaceutically acceptable salt thereof when r is hydrogen, r2 is hydrogen or methyl and r3 is chloro or methoxy.    2. the compound of claim 1 wherein r and r2 are hydrogen and   r3    is chloro,   8-chloro-6rll-dihydrodiben    [b. e.]-thiepin-11-one-3-acetic acid.    3. the compound of claim 1 wherein r and r2 are hydrogen and   r3    is methoxy,   8-methoxy-6,ll-dihydrodi-      benzo-(b.e,]-thiepin-ll-one-3-acetic    acid.    4. a pharmaceutical composition comprising a pharmaceutically acceptable non-toxic excipient and a therapeutically effective amount of a compound of claim 1.    5. a compound of claim 1 for use in a method of treating mammals.    6. process for the production of 8-r3 substituted6,11-dihydrodibenzo-[b. e.]-thiepin-11-one compounds of claim 1, which comprises one or more of the following steps:  (a) treating 3-diazoacetyl-8-r3 substituted6,11-dihydrodibenzo-[b. e.]-thiepin-11-one in the  presence of a   c1-c12    alkanol to obtain the corresponding ester . of (dl)-2- (8-r3 substituted-6,11-dihydrodibenzo [b. e.]-thiepin-11-one-3-yl) propionic acid;  (b) hydrolyzing a   c1-c12    alkyl ester of 8-r3    substituted-6,11-dihydrodibenzo-[b.e.3-thiepin-11-one-3-    acetic acid to obtain 8-r3 substituted-6,11-dihydrodibenzo-[b. e.]-thiepin-11-one-3-acetic acid;  (c) esterifying an acid of formula (ii) to obtain the corresponding   c1-c12    alkyl esters; ;  (d) converting an acid of formula (ii) to pharmaceutically acceptable salts thereof;  (e) hydrolyzing an ester of formula (ii) to obtain the corresponding free acid or salt thereof;  (f) transesterifying a lower ester of formula (ii) to obtain a higher ester thereof;  (g) transesterifying a higher ester of formula (ii) to obtain a lower ester thereof;  (h) converting a salt of formula (ii) to the corresponding free acid;  (i) converting a salt of formula (ii) to another salt by a salt interchange.    7. a compound selected from those having the formula: emi52.1        wherein r is hydrogen, an alkyl group containing from one to twelve carbon atoms, or a pharmaceutically acceptable salt thereof when r is hydrogen, rú is hydrogen, chloro or methoxy and rê is hydrogen or methyl    8. a pharmaceutical composition comprising a pharmaceutically acceptable non-toxic excipient and a therapeutically effective amount of a compound of claim 7.    9. a compound of claim 7 for use in a method of treating mammals.    10. process for the production of 6,11-dihydrodibenzo-[b.e.3-thiepin-11-one s-oxides of claim 7, which comprises one or more of the following steps:  (a) oxidizing a non-s-oxide free acid or ester, otherwise corresponding to a compound of formula   (i),    to obtain a compound of formula (i);  (b) hydrolyzing a   c1-c12    alkyl ester of formula (i) to obtain the corresponding free acid of formula (i) or salt thereof;  (c) esterifying a free acid of formula (i) to obtain the corresponding   cl-cl2    alkyl esters;  (d) converting an acid of formula (i) to a pharmaceutically acceptable salt thereof;  (e) hydrolyzing an ester of formula (i) to obtain the corresponding free acid;  (f) transesterifying a lower ester of formula (i) to obtain a higher ester thereof;  ;  (g) transesterifying a higher ester of formula (i) to obtain a lower ester thereof;  (h) converting the salts of formula (i) to the corresponding free acid;  (i) converting a salt of formula (i) to another salt by a salt interchange.  
</CLAIMS>
</TEXT>
</DOC>
